Tissue Dynamics and Galmed Collaborate on Cardiac Fibrosis Model Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: Newsfilter
- Collaborative Model Development: Tissue Dynamics and Galmed Pharmaceuticals are collaborating to develop a novel human chronic cardiac fibrosis model aimed at accelerating the discovery and development of Aramchol-based therapies, which is expected to significantly enhance the efficiency of cardiac disease treatments.
- Impact of Cardiac Fibrosis: Cardiac fibrosis is a major driver of chronic heart failure, with cardiovascular diseases accounting for approximately 20.5 million deaths annually worldwide, making the development of effective therapies crucial for public health.
- Innovative Technology Application: The new platform will combine Tissue Dynamics' multichambered cardiac organoids with embedded metabolic sensors, capable of testing over 20,000 organoids simultaneously, capturing real-time functional kinetics data, thus advancing cardiac disease research.
- Strategic Implications: This collaboration will leverage Galmed's expertise in SCD1 biology and metabolic pathway modulation, while AI-driven analysis will support rapid evaluation of Aramchol candidates, potentially transforming the development of cardiac fibrosis therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLMD
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Galmed Pharmaceuticals to Acquire Colospan in Strategic Move
- Acquisition Agreement: Galmed Pharmaceuticals has signed a definitive agreement to acquire Colospan, with the deal expected to close in Q2 2026, positioning Colospan as a wholly owned subsidiary and enhancing Galmed's market presence in colorectal surgery.
- Product Benefits: Colospan's lead product, the CG-100 intraluminal bypass device, is designed to reduce anastomotic leak complications and the need for diverting stomas after colorectal surgery, potentially improving patient recovery outcomes.
- Market Potential: The CG-100 is CE marked in Europe and currently undergoing a pivotal clinical trial in the U.S., which, if successful, could open new market opportunities for Galmed and strengthen its competitive product portfolio.
- Financial Terms: Under the deal, Colospan shareholders and SAFE holders will receive $2.5 million in cash and $2 million in Galmed shares at closing, reflecting Galmed's confidence in Colospan's future potential.
See More
Galmed Pharmaceuticals Acquires Colospan to Enhance GI Medtech Platform
- Acquisition Details: Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan for $2.5 million in cash and $2.0 million in ordinary shares, expected to close in Q2 2026, making Colospan a wholly owned subsidiary and advancing Galmed's diversified GI medtech strategy.
- Technological Integration Benefits: Colospan's CG-100 device, which has received FDA Breakthrough Device Designation, aims to reduce anastomotic leak risks in colorectal surgeries, and by leveraging Galmed's clinical expertise and resources, the acquisition is expected to accelerate the FDA application process, enhancing patient care standards.
- Market Demand Context: With approximately 1.9 million colorectal cancer cases diagnosed annually worldwide and anastomotic leaks occurring in up to 21% of procedures, leading to increased hospital stays and healthcare costs, Colospan's product addresses this clinical and economic burden, improving patient quality of life.
- Strategic Growth Outlook: This acquisition is viewed as a defining moment for Galmed, combining over 25 years of clinical execution capabilities, and is expected to expedite the CG-100 pivotal study, driving the company's growth and competitiveness in the global GI healthcare market.
See More
Tissue Dynamics Uncovers New Mechanism of Cardiac Fibrosis
- New Mechanism Discovery: Tissue Dynamics identified an unrecognized metabolic mechanism driving cardiac fibrosis using human cardiac organoid models, providing a new biological perspective for treating heart diseases that could potentially alter existing treatment strategies.
- Significant Drug Combination Effects: The combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001) in inflammatory human cardiac organoids, preserving cardiac muscle integrity and maintaining metabolic function, indicating its potential in cardiac fibrosis treatment.
- Clinical Development Prospects: Following the study results, Tissue Dynamics has filed a new patent and is preparing for future IND-enabling activities, highlighting the company's innovative capabilities and market potential in cardiac disease treatment.
- Strategic Collaboration Significance: The partnership between Galmed and Tissue Dynamics aims to leverage advanced AI technologies and human organoid models to advance research and development in cardiometabolic diseases, potentially providing more therapeutic options for fibrotic diseases and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Tissue Dynamics Uncovers New Mechanism of Cardiac Fibrosis
- New Mechanism Discovery: Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using human cardiac organoid models, providing new insights into disease biology that could facilitate the development of novel therapies.
- Significant Treatment Effects: The combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001) in inflammatory human cardiac organoids while preserving cardiac muscle integrity and metabolic function, indicating its potential in treating cardiac fibrosis.
- Clinical Development Prospects: Following the study's findings, Tissue Dynamics has filed a new patent application and is preparing for future IND-enabling activities, which will pave the way for new clinical development pathways for cardiac fibrosis and related diseases.
- Deepening Strategic Collaboration: The partnership between Galmed Pharmaceuticals and Tissue Dynamics is set to enhance its R&D strategy, leveraging advanced AI technologies and human organoid models to identify additional therapeutic opportunities for fibrotic diseases, thereby strengthening the company's competitive position in the cardiometabolic field.
See More
Galmed Pharmaceuticals Achieves Major Milestone with AM-001 Study Results
- Dose Optimization: The AM-001 study demonstrates that a single 400mg dose of Aramchol meglumine has approximately 5-fold greater bioavailability compared to 300mg of Aramchol free acid dosed twice daily, significantly enhancing drug efficacy and providing better treatment options for MASH patients.
- Clinical Trial Progress: To date, around 600 adults have received single or multiple doses of Aramchol, including 240 healthy subjects and 360 MASH patients, indicating good tolerability and potential efficacy across different populations.
- Therapeutic Potential: Aramchol has shown significant anti-fibrotic effects in clinical trials, effectively reducing liver fat and alleviating steatohepatitis, further solidifying Galmed's market position in liver disease treatment.
- Future Development Directions: Galmed plans to evaluate Aramchol in multiple pre-clinical studies for combination therapies to overcome drug resistance and enhance efficacy in GI cancer treatments, showcasing the company's strategic positioning in liver and oncology therapies.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Galmed Pharmaceuticals to Acquire Colospan in Strategic Move
- Acquisition Agreement: Galmed Pharmaceuticals has signed a definitive agreement to acquire Colospan, with the deal expected to close in Q2 2026, positioning Colospan as a wholly owned subsidiary and enhancing Galmed's market presence in colorectal surgery.
- Product Benefits: Colospan's lead product, the CG-100 intraluminal bypass device, is designed to reduce anastomotic leak complications and the need for diverting stomas after colorectal surgery, potentially improving patient recovery outcomes.
- Market Potential: The CG-100 is CE marked in Europe and currently undergoing a pivotal clinical trial in the U.S., which, if successful, could open new market opportunities for Galmed and strengthen its competitive product portfolio.
- Financial Terms: Under the deal, Colospan shareholders and SAFE holders will receive $2.5 million in cash and $2 million in Galmed shares at closing, reflecting Galmed's confidence in Colospan's future potential.
See More
Galmed Pharmaceuticals Acquires Colospan to Enhance GI Medtech Platform
- Acquisition Details: Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan for $2.5 million in cash and $2.0 million in ordinary shares, expected to close in Q2 2026, making Colospan a wholly owned subsidiary and advancing Galmed's diversified GI medtech strategy.
- Technological Integration Benefits: Colospan's CG-100 device, which has received FDA Breakthrough Device Designation, aims to reduce anastomotic leak risks in colorectal surgeries, and by leveraging Galmed's clinical expertise and resources, the acquisition is expected to accelerate the FDA application process, enhancing patient care standards.
- Market Demand Context: With approximately 1.9 million colorectal cancer cases diagnosed annually worldwide and anastomotic leaks occurring in up to 21% of procedures, leading to increased hospital stays and healthcare costs, Colospan's product addresses this clinical and economic burden, improving patient quality of life.
- Strategic Growth Outlook: This acquisition is viewed as a defining moment for Galmed, combining over 25 years of clinical execution capabilities, and is expected to expedite the CG-100 pivotal study, driving the company's growth and competitiveness in the global GI healthcare market.
See More
Tissue Dynamics Uncovers New Mechanism of Cardiac Fibrosis
- New Mechanism Discovery: Tissue Dynamics identified an unrecognized metabolic mechanism driving cardiac fibrosis using human cardiac organoid models, providing a new biological perspective for treating heart diseases that could potentially alter existing treatment strategies.
- Significant Drug Combination Effects: The combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001) in inflammatory human cardiac organoids, preserving cardiac muscle integrity and maintaining metabolic function, indicating its potential in cardiac fibrosis treatment.
- Clinical Development Prospects: Following the study results, Tissue Dynamics has filed a new patent and is preparing for future IND-enabling activities, highlighting the company's innovative capabilities and market potential in cardiac disease treatment.
- Strategic Collaboration Significance: The partnership between Galmed and Tissue Dynamics aims to leverage advanced AI technologies and human organoid models to advance research and development in cardiometabolic diseases, potentially providing more therapeutic options for fibrotic diseases and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Tissue Dynamics Uncovers New Mechanism of Cardiac Fibrosis
- New Mechanism Discovery: Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using human cardiac organoid models, providing new insights into disease biology that could facilitate the development of novel therapies.
- Significant Treatment Effects: The combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001) in inflammatory human cardiac organoids while preserving cardiac muscle integrity and metabolic function, indicating its potential in treating cardiac fibrosis.
- Clinical Development Prospects: Following the study's findings, Tissue Dynamics has filed a new patent application and is preparing for future IND-enabling activities, which will pave the way for new clinical development pathways for cardiac fibrosis and related diseases.
- Deepening Strategic Collaboration: The partnership between Galmed Pharmaceuticals and Tissue Dynamics is set to enhance its R&D strategy, leveraging advanced AI technologies and human organoid models to identify additional therapeutic opportunities for fibrotic diseases, thereby strengthening the company's competitive position in the cardiometabolic field.
See More
Galmed Pharmaceuticals Achieves Major Milestone with AM-001 Study Results
- Dose Optimization: The AM-001 study demonstrates that a single 400mg dose of Aramchol meglumine has approximately 5-fold greater bioavailability compared to 300mg of Aramchol free acid dosed twice daily, significantly enhancing drug efficacy and providing better treatment options for MASH patients.
- Clinical Trial Progress: To date, around 600 adults have received single or multiple doses of Aramchol, including 240 healthy subjects and 360 MASH patients, indicating good tolerability and potential efficacy across different populations.
- Therapeutic Potential: Aramchol has shown significant anti-fibrotic effects in clinical trials, effectively reducing liver fat and alleviating steatohepatitis, further solidifying Galmed's market position in liver disease treatment.
- Future Development Directions: Galmed plans to evaluate Aramchol in multiple pre-clinical studies for combination therapies to overcome drug resistance and enhance efficacy in GI cancer treatments, showcasing the company's strategic positioning in liver and oncology therapies.
See More
